ALDER BIOPHARMACEUTICALS INC
ALDER BIOPHARMACEUTICALS INC (ALDR): 3 pipeline candidates · ~22 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
21.6 months
D/E 2.23 · 0% dilution
Lead: BLA Filed
3 candidates
N/A
N/A
A transparent, data-derived signal for ALDER BIOPHARMACEUTICALS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$119.7M
Quarterly Burn
$59.3M
Runway
21.6 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| ald1910 | Preclinical |
| clazakizumab | Phase 2 |
| eptinezumab | BLA Filed |
Frequently asked questions
How many drug candidates are in ALDER BIOPHARMACEUTICALS INC's pipeline?
ALDER BIOPHARMACEUTICALS INC (ALDR) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ALDER BIOPHARMACEUTICALS INC's lead drug candidate?
ALDER BIOPHARMACEUTICALS INC's most advanced tracked candidate is ald1910 (Preclinical) for migraine.
What is ALDER BIOPHARMACEUTICALS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ALDER BIOPHARMACEUTICALS INC has approximately 21.6 months of cash runway.
Who is the CEO of ALDER BIOPHARMACEUTICALS INC?
Paul B. Cleveland is the chief executive officer of ALDER BIOPHARMACEUTICALS INC (ALDR).
Get the full picture on ALDER BIOPHARMACEUTICALS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.